# The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

> **NCT01556477** · PHASE2 · UNKNOWN · sponsor: **Nordic MDS Group** · enrollment: 72 (estimated)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** azacitidine + lenalidomide

## Key facts

- **NCT ID:** NCT01556477
- **Lead sponsor:** Nordic MDS Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-11
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2012-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01556477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01556477, "The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01556477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*